Drug Trial Radar · NCT03379727
Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.
Last checked: Nov 19, 2026Latest source record: Feb 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
301
Actual
Start
Feb 13, 2018
Primary completion
Jul 9, 2021
Study completion Jul 9, 2021
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 20, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to gather and evaluate additional safety and efficacy data on the combination of midostaurin and standard of care for adult patients with newly diagnosed Fms-like tyrosine kinase receptor (FLT3) mutated Acute Myeloid Leukemia (AML) who were eligible for standard induction and consolidation
Conditions
- Acute Myeloid Leukemia
Interventions
MidostaurinDrug
Induction Phase: 50 mg (two 25 mg capsules) twice a day by mouth on days 8-28, for 1 - 2 cycles; a cycle = 28 days; Consolidation Phase: 50 mg (two 25 mg capsules) twice a day by mouth on days 8-28, for up to 4 cycles; Maintenance Phase: Continuous dosing (days 1 - 28) for up yo 12 cycles or until relapse, unacceptable toxicity, death, physician's decision, subject/guardian decision, protocol deviation, study termination by Sponsor, lost to follow-up, technical problems, pregnancy, subject withdrew consent, or until the end of study, whichever event occurred first.
CytarabineDrug
Induction Phase (standard dose) (7 + 3 arm): 100-200 mg/m2/day by Continuous intravenous infusion (CIVI) days 1-7 (168 hours infusion); Induction Phase (5 + 2 arm): 100 mg/m2/day by CIVI days 1-5; Consolidation Phase: 1-3 g/m2 infusion over 3 hours every 12 h on days 1, 3 and 5, up to 4 cycles based on age and per investigator discretion
anthracycline ((daunorubicin or idarubicin): Induction Phase onlyDrug
daunorubicin (7 + 3 arm): 60-90 mg/m2/day by IV push on days 1-3 (with standard-dose cytarabine); daunorubicin (5 + 2 arm): 60 mg/m2/day by IV push on days 1-2; idarubicin (7 + 3 arm): 12 mg/m2/day by IV push on days 1-3 (with standard-dose cytarabine); idarubicin (5 + 2 arm): 12 mg/m2/day by IV push on days 1-2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients With Adverse Events (AEs), Grade 3 & 4 AEs, Serious Adverse Events (SAEs), AEs Leading to Discontinuation, and Deaths up to 24 Months (M24).Time frame: Baseline up to approximatly 24 months
Locations
86 sites in 15 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Pleven, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Varna, Bulgaria
Novartis Investigative Site
Zagreb, Croatia
Novartis Investigative Site
Brno, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Tallinn, Estonia
Novartis Investigative Site
Helsinki, Finland
Novartis Investigative Site
Oulu, Finland
Novartis Investigative Site
Tampere, Finland
Novartis Investigative Site
Besançon, France
Novartis Investigative Site
Clamart, France
Novartis Investigative Site
Créteil, France
Novartis Investigative Site
Dijon, France
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Limoges, France
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Metz, France
Novartis Investigative Site
Nice, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Pierre-Bénite, France
Novartis Investigative Site
Poitiers, France
Novartis Investigative Site
Villejuif, France
Novartis Investigative Site
Bayonne, Bayonne Cedex, France
Novartis Investigative Site
Saint Priest En Jarez, Pays de la Loire Region, France
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Szeged, Hungary
Novartis Investigative Site
Naples, Italy
Novartis Investigative Site
Naples, Italy
Novartis Investigative Site
Ancona, AN, Italy
Novartis Investigative Site
Avellino, AV, Italy
Novartis Investigative Site
Bergamo, BG, Italy
Novartis Investigative Site
Bologna, BO, Italy
Novartis Investigative Site
Brescia, BS, Italy
Novartis Investigative Site
Cuneo, CN, Italy
Novartis Investigative Site
Cosenza, CS, Italy
Novartis Investigative Site
San Giovanni Rotondo, FG, Italy
Novartis Investigative Site
Florence, FI, Italy
Showing 40 of 86 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.